nature medicine l e t t e r s Variola major (smallpox) infection claimed hundreds of millions lives before it was eradicated by a simple vaccination strategy: epicutaneous application of the related orthopoxvirus vaccinia virus (VACV) to superficially injured skin (skin scarification, s.s.) 1 . However, the remarkable success of this strategy was attributed to the immunogenicity of VACV rather than to the unique mode of vaccine delivery. We now show that VACV immunization via s.s., but not conventional injection routes, is essential for the generation of superior T cell-mediated immune responses that provide complete protection against subsequent challenges, independent of neutralizing antibodies.
l e t t e r s Variola major (smallpox) infection claimed hundreds of millions lives before it was eradicated by a simple vaccination strategy: epicutaneous application of the related orthopoxvirus vaccinia virus (VACV) to superficially injured skin (skin scarification, s.s.) 1 . However, the remarkable success of this strategy was attributed to the immunogenicity of VACV rather than to the unique mode of vaccine delivery. We now show that VACV immunization via s.s., but not conventional injection routes, is essential for the generation of superior T cell-mediated immune responses that provide complete protection against subsequent challenges, independent of neutralizing antibodies. Smallpox was eradicated worldwide by immunization with VACV delivered to skin with a bifurcated needle (s.s.) [1] [2] [3] . We tested the hypothesis that rVACV immunization via s.s. is crucial for the generation of superior protective immune responses. Using an established mouse model of VACV delivered by the s.s. route 4, 5 , we immunized C57BL/6 mice with rVACV by either s.s. or hypodermic injection routes. We found that mice vaccinated by s.s. with rVACV generated more interferon-γ (IFN-γ)-producing CD8 + T cells (Fig. 1a) , a superior recall IFN-γ response ( Fig. 1b) and superior humoral responses ( Fig. 1c,d) . We next immunized mice with rVACV by subcutaneous (s.c.) injection, with or without simultaneous epidermal disruption with a scarification needle (mock s.s.). Cellular and humoral responses were equivalent in these two groups and were inferior to the rVACV-s.s. group (Supplementary Fig. 1a,b ). Heatinactivated rVACV delivered via s.s. also failed to induce a substantial cellular or antibody response ( Supplementary Fig. 1c,d) . These data suggest that live VACV infection of disrupted epidermis is essential for the superiority of s.s over other vaccination routes. We compared viral messenger RNA and protein expression after delivery of rVACV via s.s. and s.c. routes. Despite equivalent initial viral loads ( Supplementary Fig. 2a ), s.s. delivery resulted in markedly higher viral gene expression at the inoculation site ( Supplementary Fig. 2b,c) . Epidermal and follicular keratinocytes were infected uniformly after s.s., but not s.c., immunization ( Supplementary  Fig. 2c ), resulting in a higher available antigen dose.
Skin-resident effector memory T cells (T EM cells) provide complete protection against cutaneous challenge, whereas protection against lethal respiratory challenge requires both respiratory mucosal T EM cells and central memory T cells (T CM cells). Vaccination with recombinant VACV (rVACV)
We recently showed that, after rVACV scarification, antigen-specific T cells are imprinted with skin-homing markers in draining lymph nodes (DLNs) and rapidly migrate into infected skin 4 . We predicted that rVACV delivery via s.s. route would be highly protective against cutaneous challenge. We challenged mice previously immunized with rVACV (rVACV memory mice) via various routes (s.s., s.c., intradermal (i.d.), i.m. and intraperitoneal (i.p.)) with a secondary rVACV infection to skin and measured viral load at the challenge site 6 d later. Mice immunized via s.s. had completely cleared virus from the infected site (a more than six-log viral load reduction), whereas mice immunized by all other routes showed incomplete viral clearance ( Fig. 2a) . These data indicate that s.s. rVACV vaccination induces dramatically superior protective immunity in skin.
The mode of protection against cutaneous challenge was distinct for i.p. and s.s. immunization. The moderate protection after i.p. vaccination could be abrogated by T cell depletion and was entirely absent in µMT mice, which lack the heavy (µ) chain of IgM and do not produce antibodies ( Fig. 2b) . However, the s.s.-induced protection against skin challenge remained intact in µMT mice and was significantly compromised only after T cell depletion ( Fig. 2b) . This is consistent with a significantly stronger recall T cell response after cutaneous challenge in s.s.-immunized mice compared to i.p.-immunized mice, in both wild-type (WT) and µMT mice ( Supplementary Fig. 3) . Therefore, T cell memory generated by rVACV s.s. immunization is both necessary and sufficient for the protection against cutaneous challenge.
Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity l e t t e r s
We adoptively transferred OT-I-transgenic T cells, specific for the ovalbumin peptide SIINFEKL (Ova 257-264 ), 1 d before immunization with an rVACV that expresses Ova 257-264 under the control of an early gene promoter 6 . OT-I cells were readily found in the skin of s.s.-immunized memory mice, both before ( Fig. 2c ) and 4 d after ( Fig. 2d ) secondary cutaneous challenge, indicating efficient generation and recruitment of skin-homing T EM cells by the s.s. route. We have reported previously that both VACV-specific T EM cells and VACVspecific T CM cells are generated after s.s. with rVACV 4 . We next asked whether the protective skin immunity in s.s.-immunized mice is mediated by T EM cells already resident to skin before secondary challenge, or by newly activated T CM cells from the lymph nodes. T cell egress from lymph nodes was blocked by treating mice before and during cutaneous challenge with FTY720, a sphingosine-1-phosphate antagonist that blocks egress of lymphocytes from secondary lymphoid organs 7, 8 . FTY720 treatment induced pronounced lymphocytopenia via sequestration of lymphocytes in the lymph nodes ( Fig. 2e) 7, 8 . Moreover, it led to a decrease in the number and frequency of OT-I cells in skin and a concurrent accumulation of OT-I cells in DLN in cutaneously challenged mice ( Fig. 2f ). Despite this, viral clearance from skin was unaffected by FTY720 treatment (Fig. 2g) . These results suggest that the skin-resident T EM cells generated by the original rVACV s.s. are highly effective in the control of virus upon subsequent cutaneous challenge. Activation of OT-I T CM cells in DLN and their subsequent recruitment to skin after challenge was not required for the complete and rapid elimination of virus by 6 d ( Fig. 2e-g) . Because FTY720 treatment blocked T cell egress from the lymph nodes ( Fig. 2e) , the T CM cells were unable to migrate from the lymph nodes to skin and participate in the virus clearance. Therefore, the observed viral clearance ( Fig. 2g ) was independent of T CM cells. This role of tissue-resident T EM cells is supported by recent studies -immunized mice, but not mice in the injection groups, by histopathological analysis both before and after secondary cutaneous challenge ( Fig. 2h and Supplementary Fig. 4) .
These observations explain the superior protection against cutaneous challenge afforded by rVACV s.s. immunization. These data prompted us to evaluate the efficacy of rVACV scarification for protection against a tumor challenge in skin. We challenged mice previously immunized with rVACV expressing OVA 257-264 via s.s., i.d., s.c., i.m. or i.p. routes with the OVA-expressing B16 melanoma cell line MO5 delivered i.d. (ref. 11). One week after MO5 implantation, tumor growth was evident at the injection site of unimmunized control mice (Fig. 3a) , all of which experienced rapid tumor growth and became moribund within 1 month (Fig. 3b) . By 5 weeks after challenge, s.c.-immunized mice experienced 100% mortality, i.d.-and i.m.-immunized mice showed 75% mortality and i.p.-immunized mice experienced 50% mortality (Fig. 3b) , with all surviving mice harboring large tumors (Fig. 3a) . In contrast, s.s.-immunized mice showed 100% survival by the end of the experiment (44 d after challenge) (Fig. 3b) . The tumors that did develop in s.s.-immunized mice were considerably smaller than in all other mice studied and grew much more slowly or not at all (Fig. 3a) , suggesting an ongoing immune response. These results indicate that rVACV immunization via s.s. is highly effective in generating skin-targeted memory T cells recognizing antigens on cutaneous tumors. Smallpox, caused by variola major virus, is transmitted primarily via respiratory droplets. To investigate whether rVACV scarification also provides superior protection in respiratory tissues, we intranasally challenged rVACV memory mice previously immunized by s.s., i.d., s.c., i.m. or i.p. routes with lethal doses of pathogenic Western Reserve (WR)-VACV. Mice immunized via the s.c., i.d. or i.m. routes all showed marked weight loss after challenge and were only partially protected from lethality (Fig. 4a,b) . In contrast, mice immunized by the s.s. route not only survived but were completely protected from clinical illness (as judged by absence of weight loss) ( Fig. 4a,b) . Vaccination via s.s. protected mice against the lethal respiratory challenge even at three-log lower doses of rVACV vaccine (Supplementary Fig. 5 ).
We used µMT immune mice or WT immune mice depleted of T cells to explore the mechanism of this protection against lethal intranasal challenge. After rVACV s.s. immunization, both µMT immune mice and T cell-depleted WT immune mice were fully protected from illness and death, indicating that either T cell memory or antibodies were sufficient to provide complete protection against this lethal challenge (Fig. 4c,d) . Only T cell depletion in s.s.-immunized µMT memory mice abrogated protection (Fig. 4c,d) . FTY720-treated, s.s.-immunized µMT memory mice were partially protected against the lethality of the intranasal challenge (Fig. 4e,f and Supplementary  Fig. 6 ). This suggests that protective T EM cells lining upper respiratory mucosa are generated by s.s. immunization. The two different clinical outcomes after intranasal challenge of µMT memory mice with and without FTY720 treatment suggests that activation of T CM cells in the lymph nodes draining respiratory mucosa, and the subsequent recruitment of T EM cells to the respiratory tract, are essential for full protection against respiratory infectious challenge. Collectively, these data indicate that even in the complete absence of an antibody response, VACV-specific T CM and T EM cells together provide complete protective immunity against lethal respiratory challenge in s.s.-immunized mice. 
l e t t e r s
Although smallpox has been eradicated in the wild and exists only in frozen stocks in government facilities, concerns about bioterrorism have raised questions about the need for reintroduction of widespread smallpox vaccination with VACV. However, in the absence of an established smallpox epidemic, mass vaccination of the general public with VACV is precluded by an unacceptably high incidence of morbidity after vaccination, particularly in individuals with atopic disorders [12] [13] [14] [15] [16] [17] [18] . The nonreplicating MVA is an attractive alternative to VACV, as it has an impressive safety profile [19] [20] [21] [22] . MVA vaccines are typically delivered by i.m. injection. Skin scarification has not been tested in MVA vaccination studies. We immunized C57BL/6 mice with MVA via s.s. This procedure elicited cellular and humoral immune responses to VACV in a dose-dependent manner and provided dose-dependent protection against lethal intranasal challenge with WR-VACV (Supplementary Fig. 7) . Notably, a single immunization with 2 × 10 6 plaque-forming units (PFU) of MVA via the s.s. route, but not i.m. injection, provided complete protection against morbidity and mortality in this model (Fig. 4g,h) . This result is consistent with the markedly stronger immune responses after MVA s.s. immunization (Supplementary Fig. 8) .
Taken together, the data presented here establish that immunization with rVACV vaccines, including nonreplicative strains, via superficially injured skin (that is, s.s.), provides robust and anatomically flexible protection associated with a highly effective peripheral T EM and T CM cell response without requirement for neutralizing antibodies. The mechanism by which s.s. is so much more effective than other immunization routes is incompletely understood. VACV infection of epidermal keratinocytes after s.s. may trigger a cascade of proinflammatory molecule production [23] [24] [25] , as well as provide a higher dose of antigen, both of which may enhance the generation of optimal immunity. We hope that these insights will pave the way for the design of safe affordable and effective VACV-based immunization for infectious diseases and cancer.
METHodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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Mice, viruses and infection. Our experiments using mice were in compliance with the guidelines set out by the Center for Animal Resources and Comparative Medicine at Harvard Medical School. C57BL/6 and µMT mice were from Jackson Laboratory. We bred Thy1.1 + OT-I Rag1 -/mice in a Harvard Medical School animal facility. We expanded and titered rVACV expressing both EGFP and the OT-I T cell epitope OVA 257-264 (ref. 6 ) and WR-VACV stocks by standard procedures 26 . We immunized mice with 2 × 10 6 PFU VACV or MVA (ACAM3000MVA) via the s.s., i.d., s.c., i.m., or i.p. routes. We performed s.s. as previously described 4 . Six weeks after immunization, we challenged mice either cutaneously with rVACV (2 × 10 6 PFU) or intranasally with WR-VACV (2 × 10 6 PFU). For histology and FTY720 treatment studies, we challenged mice at 15 and 16 weeks after immunization, respectively. We killed mice that had lost over 25% of their original body weight.
Intracellular cytokine staining.
To prepare target cells, we infected naive C57BL/6 splenocytes with rVACV at a multiplicity of infection of 5 for 8 h followed by three washes. We incubated splenocytes from immunized and control mice with target cells (1:1 ratio) in a 96-well plate for 6 h in the presence of GolgiStop (BD Pharmingen) and subsequently performed surface and intracellular staining with the Cytoperm/Cytofix kit (BD Pharmingen) according to the manufacturer's protocol. We used antibodies (BD Pharmingen) to mouse CD16/CD32 (2.4G2), CD3e (conjugated to FITC) (145-2C11), CD8α (conjugated to PerCP) (53-6.7), IFN-γ (conjugated to phycoerythrin) (XMG1.2) and IFN-γ isotype control (X40, catalog number 340760) for XMG1.2. We analyzed samples on a FACSCanto flow cytometer (Becton Dickinson). We analyzed data with FlowJo software (Tree Star).
In vitro re-stimulation assay. We cultured target cells (prepared as described above) with splenocytes or inguinal (draining) lymph node cells from immune or control mice (1:1 ratio) in 96-well plates for 48 h. We measured IFN-γ concentration in the supernatant by ELISA using monoclonal antibody pairs to IFN-γ (BD Pharmingen), according to the manufacturer's instructions.
Enzyme-linked immunosorbent assay for serum vaccinia-specific antibody.
We coated ELISA plates with rVACV-infected HeLa cell lysates at 4 °C overnight, blocked the plates with PBS containing 10% FCS and 0.1% Tween-20 for 2 h and then added serum sample dilutions and incubated the plates at 4 °C for 1 h. We detected antibody with horseradish peroxidase-conjugated goat antibody to mouse IgG (Southern Biotech) and tetramethylbenzidine substrate reagent (BD Pharmingen). We determined A 450 with a Vmax Spectrophotometer (Molecular Devices) and calculated end-point titers as the highest dilution with an absorbance value >0.10 after subtraction of background wells assayed without antigen.
Determination of cutaneous viral load.
We determined skin viral load by real-time PCR, as previously described 4 .
In vivo depletion of T cells. We injected mice i.p. with antibody to mouse CD8 (clone 2.43, 0.5 mg) and mouse CD4 (clone GK1.5, 0.5 mg) (Bio X Cell) 2 d before and on days 0, 4 and 8 after secondary challenge. This regimen depleted >99% of CD8 + and CD4 + T cells (data not shown).
Adoptive transfer and detection of OT-I cells in skin.
We intravenously injected 2 × 10 5 OT-I cells from Thy1.1 + OT-I Rag1 -/mice into Thy1.2 + C57BL/6 mice 1 d before rVACV s.s. on ear skin (2 × 10 6 PFU). We challenged mice with 2 × 10 6 PFU rVACV on the ear 6 weeks after immunization and collected ears and blood samples either before challenge or 4 d after challenge. We separated ears into dorsal and ventral halves and incubated them in HBSS containing 1 mg ml -1 collagenase A and 40 µg ml -1 DNase I (Roche Diagnostics) at 37 °C for 2 h. We then added HBSS containing 2 mM EDTA and 5% FCS to stop the digestion. After filtering the cell suspension through 70-µm cell strainers and red cell removal, we stained cells with CD45.2-specific antibody conjugated to phycoerythrin (104) and Thy1.1-specific antibody conjugated to PerCP (OX-7) (BD Pharmingen) for flow cytometry analysis. FTY720 treatment. Sixteen weeks after rVACV s.s. immunization, we i.p. injected previously immunized mice daily with 1 mg per kg body weight FTY720 (2-amino-2-(2[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride, provided by V. Brinkmann at Novartis Pharmaceuticals) or PBS (mock control). After one or two doses, we challenged the mice cutaneously or intranasally.
Immunohistochemical staining for T cells in skin. We challenged WT mice immunized with rVACV via the s.s. or i.p. route on tail skin at 15 weeks after immunization. We collected challenged skin tissues either 1 d before or 4 d after challenge. We performed sectioning and immunohistochemical staining of skin samples for CD3 + T cell detection as previously described 4 . We obtained images with a Nikon E600 microscope and a Nikon EDX-35 digital camera.
Tumor challenge. Six weeks after rVACV immunization, we i.d. challenged memory and control naive mice with 3 × 10 5 MO5 cells, an ovalbumin gene-transfected B16 melanoma cell line 11 . We measured the longest diameter (L) and the perpendicular diameter (W) of the local tumor on days 9, 12, 18, 25, 30, 37 and 44 after challenge and calculated tumor volume with the formula 4πW 2 L / 3.
Statistical analysis.
We performed statistical comparisons with two-tailed unpaired Student's t test, Mann-Whitney test (for viral load data) and log-rank test (for survival curves) using Prism software. We used area under the curve to compare weight loss between groups. P < 0.05 was considered significant.
Additional methods. Detailed methodology is described in the Supplementary Methods. 
